182 reports of this reaction
1.6% of all KETOTIFEN FUMARATE reports
#8 most reported adverse reaction
FATIGUE is the #8 most commonly reported adverse reaction for KETOTIFEN FUMARATE, manufactured by Alcon Laboratories, Inc.. There are 182 FDA adverse event reports linking KETOTIFEN FUMARATE to FATIGUE. This represents approximately 1.6% of all 11,458 adverse event reports for this drug.
Patients taking KETOTIFEN FUMARATE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for KETOTIFEN FUMARATE, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for KETOTIFEN FUMARATE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 182 FDA reports for KETOTIFEN FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 1.6% of all adverse event reports for KETOTIFEN FUMARATE, making it a notable side effect.
If you experience fatigue while taking KETOTIFEN FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.